Sophiris Bio Inc. (NASDAQ:SPHS) shares were down 3.4% during mid-day trading on Thursday . The company traded as low as $2.55 and last traded at $2.59, with a volume of 760,134 shares trading hands. The stock had previously closed at $2.68.

A number of research analysts have issued reports on SPHS shares. Maxim Group restated a “buy” rating and set a $4.00 price target on shares of Sophiris Bio in a research note on Thursday, March 24th. Echelon Wealth Partners reiterated a “buy” rating and issued a $5.00 price objective on shares of Sophiris Bio in a research note on Friday, June 10th.

The firm has a 50 day moving average price of $1.82 and a 200-day moving average price of $1.63. The firm’s market cap is $53.91 million.

Sophiris Bio (NASDAQ:SPHS) last posted its quarterly earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.06. Equities research analysts forecast that Sophiris Bio Inc. will post ($0.73) EPS for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.